WebMay 13, 2016 · Drug: CB-839 Drug: Nivolumab: Phase 1 Phase 2: Study Design. Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. Layout table for study information; Study Type : Interventional (Clinical Trial) WebFeb 26, 2014 · CB-Cabo: patients with histologically confirmed diagnosis of locally-advanced, inoperable or metastatic RCC treated with cabozantinib in combination with …
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors - Full Text View - ClinicalTrials.gov
WebCB-839 (CB839;CB 839;Telaglenastat) Catalog No.: PC-42933 Not For Human Use, Lab Use Only. CB-839 (Telaglenastat) is a potent, selective, and orally bioavailable inhibitor of glutaminase with IC50 of 28 and 23 nM for glutaminase in kidney and brain (GAC and KGA), but not the liver form of glutaminase (GLS2, IC50>1 uM). WebDec 31, 2024 · CB-839 did not affect the OCR:ECAR response to DCA, whereas diclofenac strongly inhibited ECAR and further increased the OCR:ECAR ratio. We conclude that in melanoma cell lines, DCA reduces proliferation through reprogramming of cellular metabolism and synergizes with other metabolically targeted drugs. swapit clothing
Telaglenastat (CB-839) ≥99%(HPLC) - selleckchem
WebOct 5, 2024 · However, single-drug treatment of CB-839 only showed a very limited anti-tumor effect in most GD liver cancer cells. High-throughput screenings, such as genome-wide CRISPR screen, should be applied to discover the functionally important genes responsible for glutamine dependence or CB-839 sensitivity in liver cancer. WebStore lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. … WebCB-839 is a potent, selective, and orally bioavailable inhibitor of both splice variants of glutaminase (KGA and GAC). CB-839 had antiproliferative activity in a triple-negative … skipwith elementary school henrico va